GlobeNewswire Inc | Sep 17, 2020 05:06PM EDT

September 17, 2020

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, spoke to Jeremy Abbate, Publisher of Scientific American, in its inaugural fireside chat series 18 Minutes With on Wednesday September 16, 2020 at 4:00 p.m. EDT.

A replay of the live streaming event 18 Minutes With: Dr. Jennifer Buell is available at https://www.scientificamerican.com/custom-media/cancer-covid-19-and-access-to-combination-therapies/

In the interview with Jeremy Abbate, Dr. Buell discusses Agenus immunotherapies in the fight against COVID-19, the importance of combination therapies and the need for improved patient access, and the rapidly changing I-O landscape.

About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered inLexington, MA.For more information, please visitwww.agenusbio.comand our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:

Agenus Inc. Jennifer Buell, PhD 781-674-4420Jennifer.Buell@agenusbio.com